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After spinal cord injury (SCI), astrocytes become hypertrophic, and proliferative, forming
a dense network of astroglial processes at the site of the lesion. This constitutes a
physical and biochemical barrier to axonal regeneration. Mitochondrial fission regulates
cell cycle progression; inhibiting the cell cycle of astrocytes can reduce expression levels
of axon growth-inhibitory molecules as well as astroglial scar formation after SCI. We
therefore investigated how an inhibitor of mitochondrial fission, Mdivi-1, would affect
astrocyte proliferation, astroglial scar formation, and axonal regeneration following SCI in
rats. Western blot and immunofluorescent double-labeling showed that Mdivi-1 markedly
reduced the expression of the astrocyte marker glial fibrillary acidic protein (GFAP), and
a cell proliferation marker, proliferating cell nuclear antigen, in astrocytes 3 days after
SCI. Moreover, Mdivi-1 decreased the expression of GFAP and neurocan, a chondroitin
sulfate proteoglycan. Notably, immunofluorescent labeling and Nissl staining showed
that Mdivi-1 elevated the production of growth-associated protein-43 and increased
neuronal survival at 4 weeks after SCI. Finally, hematoxylin-eosin staining, and behavioral
evaluation of motor function indicated that Mdivi-1 also reduced cavity formation and
improved motor function 4 weeks after SCI. Our results confirm that Mdivi-1 promotes
motor function after SCI, and indicate that inhibiting mitochondrial fission using Mdivi-1
can inhibit astrocyte activation and astroglial scar formation and contribute to axonal
regeneration after SCI in rats.
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INTRODUCTION
Spinal cord injury (SCI) is a global medical problem. It often leads to very limited regeneration
of damaged axons and subsequent permanent functional impairment, the exact mechanisms of
which remain to be elucidated (Silver and Miller, 2004; Tuszynski and Steward, 2012). The lack
of spontaneous anatomical and functional repair is due not merely to an intrinsic inability of
the neuron to regenerate its injured axon, but also to the presence of an inhospitable local
environment in the lesion site constituting a physical and biochemical barrier—the so-called glial
scar—composed essentially of reactive astrocytes (Silver andMiller, 2004). Astrocytes are the major
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cell type in the spinal cord and provide a variety of critical
supportive functions that establish and maintain neuronal
homeostasis (Tian et al., 2006). However, after SCI, they become
hypertrophic and proliferative, and form a physical barrier at the
site of injury, which significantly impedes axonal regeneration
(Lin et al., 2014). In addition, chondroitin sulfate proteoglycans
(CSPGs) form a biochemical barrier which also plays a crucial
part in regeneration failure (Yiu and He, 2006; Gervasi et al.,
2008; Jefferson et al., 2011). Therefore, inhibition of astrocyte
activation, astroglial scar formation and CSPG production would
create a favorable environment for axonal regeneration.
Astrocytes undergo cell division following SCI. Therefore, a
possible approach for promoting axonal regeneration after SCI
would be by inhibiting the division of cells that contribute to
glial scar formation or by reducing production and secretion
of inhibitory molecules (Karimi-Abdolrezaee and Billakanti,
2012). Mitochondria are organelles that are essential for a
diverse range of important cellular functions, including cell
metabolism, growth, differentiation, survival, and programmed
cell death (DiMauro and Schon, 2008; Green and Van Houten,
2011). Recently, mitochondria were demonstrated to undergo
frequent fission, and fusion (Cao et al., 2013), which are
integrated with cell cycle progression (Mitra et al., 2009;
Qian et al., 2012). Dynamin-related protein 1 (Drp1)-mediated
mitochondrial fission is required for the proper progression of
the cell cycle phases following G1/S transition. Thus, inhibition
of mitochondrial division might be an important way to inhibit
cell mitosis. However, it is unclear whether this would inhibit
astrocyte activation and astroglial scar formation after SCI.
Mitochondrial division inhibitor 1 (Mdivi-1) is the most
effective pharmacological inhibitor of mitochondrial division
(Tanaka and Youle, 2008). It can cross the blood—brain barrier,
and its half-life is about 12 h (Cui et al., 2016). Notably, Mdivi-1
exerts a protective effect in SCI (Li G. et al., 2015), spinal cord
ischemia—reperfusion injury (Liu et al., 2015), acute cerebral
ischemic injury (Cui et al., 2016), and seizures (Xie et al., 2013),
and can also inhibit the proliferation, invasion and metastasis
of breast cancer (Zhao et al., 2013) and ovarian cancer (Wang
et al., 2015). However, the physiological and pathological roles of
Mdivi-1 in astrocyte proliferation and astroglial scar formation
after SCI are not yet known. Therefore, in the present study,
we investigate the effects of Mdivi-1 on astrocyte proliferation,
neurocan production, astroglial scar formation, and axonal
regeneration after SCI in rats.
MATERIALS AND METHODS
Animals and Experimental Design
Adult female Sprague—Dawley rats, weighing 250–300 g, were
provided by the Experiment Animal Center of Jinzhou Medical
University. All experimental procedures were approved by the
Institutional Animal Care and Use Committee of Jinzhou
Medical University. Rats were randomly divided into three
groups: SCI (Li G. et al., 2015), SCI + Mdivi-1 (Park et al.,
2011), and sham (T9–11 laminectomy only). In the Mdivi-1
group, the rats were injected with Mdivi-1 (25mg/kg i.p.; Sigma-
Aldrich, St. Louis, MO) immediately after SCI and every 24 h
thereafter for 3 or 9 days (Lin et al., 2014; Cui et al., 2016). Rats
in the sham and SCI groups received an equivalent volume of
dimethyl sulfoxide. Each group was then equally and randomly
divided into three subgroups for the following experiments: (A)
motor function test; (B) Western blot; and (C) histology (double
immunofluorescent labeling, hematoxylin-eosin staining, and
Nissl staining). The rats in all groups were sacrificed 3 days or
4 weeks after injury or laminectomy.
SCI Model Establishment
Rats were anesthetized using pentobarbital sodium (40mg/kg,
i.p.). The weight-drop model of SCI was established as described
previously (Li G. et al., 2015). In brief, the skin and muscle
overlying the spinal column were incised and a laminectomy
was performed at T9–11, leaving the dura intact. A 20 g weight
was then dropped onto the exposed T10 region of the spinal
cord from a height of 25.0mm. Postoperatively, all animals
received an injection of 0.9% normal saline (30ml/kg) to prevent
postoperative dehydration. Rats were housed individually in
cages under a 12 h light/dark cycle, with free access to food and
water, and underwent assisted urination three times per day after
SCI throughout the study.
Motor Function Evaluation
The motor function of rats in each group was evaluated using
the Basso, Beattie, and Bresnahan (BBB) scale at 3 days and 4
weeks after SCI, as described previously (Li G. et al., 2015). The
experiments were performed six independent times.
Western Blot
Spinal cords were removed 3 days or 4 weeks after SCI. The
protein lysates were fractioned on 6 or 10% SDS-polyacrylamide
gels, and then transferred to 0.45µm polyvinylidene fluoride
membranes. The membranes were blocked with 0.1% bovine
serum albumin for 1 h, then incubated overnight at 4◦C
with primary antibodies against glial fibrillary acidic protein
GFAP (ab7260, 1:2000), neurocan (ab31979, 1:300), proliferating
cell nuclear antigen (PCNA; ab29, 1:1000), growth-associated
protein-43 (GAP-43; ab16053, 1:1000) (all from Abcam, USA),
and β-actin (C4; sc-47778, 1:1000; Santa Cruz Biotechnology,
Inc., USA). The membranes were then incubated with the
corresponding second antibody: goat anti-rabbit or anti-mouse
IgG-HRP (sc-2004 or sc-2005; 1:2000; Santa Cruz Biotechnology)
at room temperature for 1 h. The remaining steps were
performed as described in our previous study (Li G. et al.,
2015), and the protein bands were analyzed using NIH Image
J software. Grayscale values of bands corresponding to GFAP,
PCNA, neurocan, and GAP-43 were normalized to that of β-actin
to determine expression levels of the proteins of interest. The
experiments were performed six independent times.
Immunofluorescent Double Labeling
At 3 days and 4 weeks after surgery, the injured spinal cords
from rats in all groups were fixed in 4% paraformaldehyde,
immersed in 30% sucrose, embedded in compound 4583,
and then sectioned on a freezing microtome as described
previously (Li G. et al., 2015). Serial 5-µm-thick transverse
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FIGURE 1 | Mdivi-1 increases the expressions of GFAP and PCNA in astrocytes at 3 days after SCI. (A–C) Western blot analysis and quantitative analysis of
GFAP (A,B) and PCNA (A,C) (n = 6, respectively). (D–F) PCNA/GFAP/DAPI triple labeling and quantitative analysis of GFAP (D,E) and PCNA (D,F) in astrocytes (n =
6, respectively). White arrows indicate proliferative astrocytes. The expression of PCNA and GFAP, and the number of GFAP-positive cells and PCNA-positive
astrocytes, were greater in the SCI group than in the sham group. PCNA and GFAP expression, and the number of GFAP-positive cells and PCNA-positive astrocytes
were lower in the Mdivi-1 group than in the SCI group. *P < 0.01 vs. Sham. #P < 0.01 vs. SCI.
Frontiers in Cellular Neuroscience | www.frontiersin.org 4 October 2016 | Volume 10 | Article 241
Li et al. Mdivi-1 Inhibits Astroglial Scar Formation
frozen sections from the epicenter of the SCI were used
for immunofluorescent double labeling and hematoxylin-eosin
staining. After permeabilizing the cells and blocking non-specific
binding sites, these spinal cord tissue sections were incubated
with the following primary antibodies diluted in 5% normal
goat serum (005-000-121, Jackson): anti-GFAP (ab7260, 1:500),
anti-neurocan (ab31979, 1:50), anti-PCNA (ab29, 1:200), anti-
GAP-43 (ab16053, 1:200) (all fromAbcam, USA), and anti-NeuN
(MAB377X, 1:50; Millipore, USA) in a humidified chamber
overnight at 4◦C. Tissue sections were incubated with the
secondary antibodies Alexa Fluor 488 goat anti-rabbit IgG (H+L;
A-11034, 1:250; Thermo Fisher Scientific, USA) and Alexa Fluor
594 goat anti-mouse IgG (H+L; A-11005, 1:250; Thermo Fisher
Scientific) for 1 h at room temperature in the dark. After
immunostaining, the sections were incubated with 1µg/ml 4′,6-
diamidino-2-phenylindole (DAPI) for 5 min in the dark to
mark the nuclei. Negative control sections were incubated with
phosphate-buffered saline in place of the primary antibody. The
sections were visualized under a fluorescent microscope (Leica
DMI4000B, Germany) connected to an Olympus Magnafire
digital camera (Olympus Corp., Melville, NY, USA). Each
fluorescent color was photographed under the same fluorescence
microscopy settings. To avoid counting the same cell in more
than one section, we counted every 11th section (100µm apart).
Immunopositive cells (those showing red or green fluorescence)
were counted using the counting function in Photoshop CS3,
and expressed as a percentage of the total number of cells
(those showing blue fluorescence) (Li G. et al., 2015). Mean
fluorescence intensity was used to quantify neurocan andGAP-43
expression, measured using Image J. Mean fluorescence intensity
= Integrated Density/Area (Tian et al., 2006). The experiments
were performed six independent times.
Nissl Staining
The 5µm transverse frozen sections were dried and then soaked
overnight in a 1:1 mixture of alcohol and chloroform in the dark
at 22 ± 1◦C. The following day, the sections were rehydrated,
and stained in 0.1% cresyl violet solution (Sigma, St. Louis,
MO, USA) for 5 min. Differentiation, dehydration, and rinsing
was performed as described previously (Li H.-T. et al., 2015).
The sections were then mounted with Permount (Beyotime
Institute of Biotechnology, Shanghai, China) and observed under
a light microscope (Olympus) equipped with a CCD camera
(Leica DMI4000B, Germany). Surviving neurons were counted
using Photoshop CS3. The experiments were performed six
independent times.
Hematoxylin-Eosin Staining
To measure the cavity area of spinal cord tissue in each group
after SCI, animals in all groups were sacrificed 4 weeks after
injury. Spinal cord tissue was cut into frozen sagittal sections
of 5µm thickness. Spinal cord tissue was prepared, cut into
frozen sagittal sections of 5µm thickness, and stained with
hematoxylin-eosin, as described previously (Tian et al., 2006)
and examined with a light microscope (Olympus) equipped with
a CCD camera (Leica DMI4000B). The maximum area of the
cavity in the sagittal sections including the damage epicenter
was measured in Photoshop CS3, using the area analysis
function. The experiments were performed six independent
times.
Statistical Analysis
All data are expressed as mean ± standard deviation (SD), and
were analyzed using one-way analysis of variance (ANOVA) with
the least significant difference (LSD) post hoc test. SPSS version
19.0 was used for all analysis. P< 0.05 was considered statistically
significant.
RESULTS
Mdivi-1 Inhibits Astroglial Proliferation at 3
Days after SCI
Astrocytes upregulate the expression of GFAP, a widely
recognized astrocyte marker, and form a physical barrier at
the site of injury that impedes axonal regeneration (Lin et al.,
2014). PCNA is known to be a reliable marker of proliferating
cells (Tian et al., 2006). We used western blots to investigate
astroglial proliferation after Mdivi-1 treatment. GFAP and PCNA
expression were significantly greater in the SCI group (0.42 ±
0.08 and 0.40 ± 0.06, respectively) than in the sham group (0.15
± 0.05 and 0.11 ± 0.03), indicating that astroglial proliferation
was induced after SCI (P < 0.01) (Figures 1A–C). In the Mdivi-1
group (0.26± 0.06 and 0.21± 0.06), GFAP and PCNA expression
were lower than in the SCI group which suggests that Mdivi-1
inhibits astroglial proliferation (P < 0.01).
Double immunofluorescence labeling of PCNA/GFAP was
performed to confirm astrocyte proliferation, in combination
with the nuclear marker DAPI. Thus, proliferative astrocytes
were visible as PCNA/GFAP/DAPI-positive cells, showing red
dots (PCNA) in a green cells (GFAP) with a blue nucleus (DAPI).
Not all GFAP-positive cells were positive for PCNA, and some
GFAP-negative cells were positive for PCNA (Figures 1D–F).
There were more GFAP-positive cells and PCNA-positive
astrocytes in the SCI group (0.43 ± 0.06 and 0.59 ± 0.11,
respectively) than in the sham group (0.17 ± 0.03 and 0.04 ±
0.02). However, there were fewer GFAP-positive cells and PCNA-
positive astrocytes in the Mdivi-1 group (0.25 ± 0.05 and 0.36 ±
0.05) than in the SCI group (P < 0.01). These findings indicate
that inhibition of mitochondrial division by Mdivi-1 can inhibit
astroglial proliferation after SCI.
Mdivi-1 Decreases the Expressions of
GFAP and Neurocan at 4 Weeks after SCI
Neurocan is a CSPG produced mainly by astrocytes (Jones
et al., 2003; Silver and Miller, 2004). We used Western blots to
investigate neurocan expression after SCI with or without Mdivi-
1 treatment. GFAP and neurocan expression in the SCI group
(0.72 ± 0.12 and 0.62 ± 0.10, respectively) were significantly
greater than in the sham group (0.15 ± 0.04 and 0.21 ± 0.04;
P < 0.01). However, expression of GFAP and neurocan in the
Mdivi-1 group (0.33 ± 0.05 and 0.40 ± 0.08, respectively) was
lower than in the SCI group. This suggests that Mdivi-1 inhibits
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FIGURE 2 | Mdivi-1 decreases the expressions of GFAP and neurocan at 4 weeks after SCI. (A–C) Western blot analysis and quantitative analysis of GFAP
(A,B) and neurocan (A,C) (n = 6, respectively). (D–F) Neurocan/GFAP/DAPI triple labeling and quantitative analysis of GFAP (D,E) and neurocan (D,F) in astrocytes
(n = 6, respectively). Compared with the sham group, the expression of GFAP and neurocan, number of GFAP-positive cells, and mean fluorescence intensity of
neurocan were elevated after SCI. GFAP, neurocan expression, number of GFAP-positive cells, and mean fluorescence intensity of neurocan were lower in the Mdivi-1
group than in the SCI group. *P < 0.01 vs. Sham. #P < 0.01 vs. SCI.
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neurocan production after SCI (P < 0.01), which might reduce
the biochemical barrier to axonal regeneration (Figures 2A–C).
Double immunofluorescence labeling for neurocan and
GFAP was performed to further characterize the production and
secretion of neurocan in astrocytes after SCI with or without
Mdivi-1 treatment. Triple-positive neurocan/GFAP/DAPI-
positive cells were observed. Neurocan (red dots) was distributed
mainly in the extracellular matrix and cytoplasm of astrocytes
(green); nuclei appeared blue. Expression of GFAP and neurocan
was lower in the SCI group (0.54 ± 0.10 and 0.064 ± 0.012,
respectively) than in the sham group (0.17 ± 0.02 and 0.011
± 0.003; P < 0.01). Furthermore, in the Mdivi-1 group, the
number of GFAP-positive cells and mean fluorescence intensity
of neurocan (0.26 ± 0.08 and 0.040 ± 0.007, respectively)
were lower than in the SCI group (P < 0.01). These findings
indicate that astrocyte proliferation and neurocan expression and
secretion were inhibited by Mdivi-1 after SCI (Figures 2D–F).
Mdivi-1 Increases the Expressions of
GAP-43 at 4 Weeks after SCI
GAP-43 is a cytoplasmic and membrane-associated protein
located mainly in neuronal growth cones and upregulated within
growing neurites (Benowitz and Routtenberg, 1997; Irwin and
Madsen, 1997). Western blots were used to investigate GAP-
43 expression after SCI with or without Mdivi-1 treatment.
Compared with the sham group (0.20 ± 0.06), the expression
of GAP-43 was significantly greater after SCI (0.50 ± 0.09; P <
0.01). Moreover, GAP-43 expression was greater in the Mdivi-
1 group (0.75 ± 0.15) than in the SCI group (P < 0.01), which
suggests that Mdivi-1 enhances axonal regeneration after SCI
(Figures 3A,B).
Immunofluorescent staining of GAP-43 was performed to
further identify it in neurons after Mdivi-1 treatment. Higher
magnification indicated that the GAP-43/NeuN/DAPI triple-
labeled neurons had green, punctate GAP-43 dots in red
neurons with a blue nucleus. The percentage of neurons
and mean fluorescence intensity of GAP-43 were calculated.
Not all neurons were positive for GAP-43 (Figure 3C). In
the SCI group, the percentage of neurons (3.6 ± 0.7) was
lower than in the sham group (8.6 ± 1.1), whereas the
mean fluorescence intensity of GAP-43 was greater (0.022
± 0.005) than in the sham group (0.009 ± 0.003; P <
0.01). Compared with the SCI group, the percentage of
neurons and GAP-43 expression were both higher in the
Mdivi-1 group (5.7 ± 0.9 and 0.049 ± 0.009; P < 0.01).
These findings provide evidence that axonal regeneration
and neuronal survival were enhanced by Mdivi-1 after SCI
(Figures 3C–E).
Mdivi-1 Decreases the Number of
Surviving Neurons at 4 Weeks after SCI
To determine the effects of Mdivi-1 on spinal cord tissue, Nissl
staining was used to illustrate the injured areas in the different
groups. The surviving neurons in the sections were subsequently
FIGURE 3 | Continued
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FIGURE 3 | Mdivi-1 increases the expressions of GAP-43 at 4 weeks after SCI. (A,B) Western blot analysis (A) and quantitative analysis of GAP-43 (B) (n = 6,
respectively). (C–E) Cells triple-labeled for GAP-43/NeuN/DAPI and quantification of NeuN (C,D) and GAP-43 (C,E). White arrows: neurons indicate GAP-43.
Expression of GAP-43 was greater in the SCI group than in the sham group, and the percentage of neurons was lower. Compared with the SCI group, Mdivi-1 can
increase GAP-43 expression and the percentage of surviving neurons. *P < 0.01 vs. sham. #P < 0.01 vs. SCI.
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examined at a higher magnification. The number of surviving
neurons was lower in the SCI group than in the sham group (P
< 0.01); however, the number of surviving neurons was greater
in the Mdivi-1 group than in the SCI group (P < 0.01). These
results demonstrate the significant protective effect of Mdivi-1
(Figure 4).
Mdivi-1 Decreases the Cavity Formation at
4 Weeks after SCI
The size of the cavity in the spinal cord can reflect astroglial
scar formation after SCI (Tian et al., 2006). Compared with the
sham group (0.20 ± 0.10mm2), the cavity area was significantly
greater after SCI (4.5 ± 0.8mm2, P < 0.01). Compared with
the SCI group, the cavity area was smaller in the Mdivi-1 group
(2.9 ± 0.6mm2, P < 0.01), which suggests that Mdivi-1 inhibits
astroglial scar formation after SCI (Figure 5).
Mdivi-1 Improves the Hindlimb Motor
Function at 3 Days and 4 Weeks after SCI
The BBB locomotor rating scores were assessed at 3 days and 4
weeks after SCI. Compared with the sham group (3 days, 20.6
± 0.6; 4 weeks, 20.6 ± 0.6), the BBB scores were significantly
lower after SCI (2.0 ± 0.8 and 9.3 ± 1.1, respectively; P < 0.01).
Compared with the SCI group, the BBB scores were significantly
greater in the Mdivi-1 group at 3 days and 4 weeks (4.0 ± 0.8
and 13 ± 1.3, respectively; P < 0.01). These findings support the
neuroprotective effect of Mdivi-1 (Figure 6).
DISCUSSION
Astrocytes are the most abundant glial cells in the central nervous
system (CNS). In chronic SCI, they become hypertrophic
and proliferative (Wilhelmsson et al., 2006), upregulate the
production of inhibitory CSPG (Bradbury et al., 2002; Su et al.,
FIGURE 4 | Mdivi-1 decreases the number of surviving neurons at 4 weeks after SCI. (A) Histological assessments of spinal cord tissue. Black arrows:
surviving neurons. (B) Quantification of surviving neurons. The number of surviving neurons was lower in the SCI group than in the sham group. Compared with the
SCI group, the number of surviving neurons was lower in the Mdivi-1 group. *P <0.01 vs. sham. #P < 0.01 vs. SCI.
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FIGURE 5 | Mdivi-1 decreases the cavity formation at 4 weeks after SCI. (A) Representative hematoxylin-eosin staining micrographs show cavity formation in
each group after SCI. (B) Quantification of cavity area shows that Mdivi-1-treated animals had significantly smaller spinal cord cavities compared than those in the SCI
group. *P < 0.01 vs. Sham. #P < 0.01 vs. SCI.
2011), and eventually contribute to the formation of an astroglial
scar that might hinder axonal regeneration in chronic SCI (Lin
et al., 2014). Finding effective ways to inhibit glial scar formation
and enhance axon regeneration is essential after SCI. To our
knowledge, this study is the first study to confirm that Mdivi-
1 inhibits astrocyte activation and astroglial scar formation, and
contributes to axonal regeneration as well as recovery of motor
function after SCI in rats.
Cell cycle regulation is a relatively new research direction in
nerve repair therapy (Zhu et al., 2007). Restarting of the cell
cycle plays a key role in astroglial activation and proliferation
after SCI (Byrnes et al., 2007; Zhu et al., 2007; Lin et al.,
2014). Administration of olomoucine, flavopiridol, and MEK
can decrease neuronal cell death and inhibit glial proliferation
after SCI. These agents reduce axon growth-inhibitory molecule
expression and astroglial scar formation at the site of injury by
inhibiting the cell cycle in vivo (Tian et al., 2006; Byrnes et al.,
2007; Li et al., 2011; Wu et al., 2011; Lin et al., 2014). Moreover,
cell cycle inhibition protects against traumatic brain injury
by reducing glial proliferation and scar formation in rats (Di
Giovanni et al., 2005). Results from an astrocyte scratch-wound
model showed that scratch damage can significantly promote the
proliferation of cultured astrocytes and increase the number of
5-bromo-deoxyuridine-positive cells in vitro (Yang et al., 2009).
Cyclins and PCNA expression increased significantly after SCI
(Tian et al., 2006), suggesting that astrocytes proliferate and then
form a dense glial scar in the damaged area, thus preventing
normal reconstruction of axons and functional recovery after SCI
in vivo. Previous studies found that PCNA expression peaked 3
days after SCI (Tian et al., 2006), and that changes in glial scars
and motor function reached a plateau in rats at 4 weeks after
SCI (Hu et al., 2010; Li et al., 2011). So we chose 3 days and
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FIGURE 6 | Mdivi-1 improves the hindlimb motor function at 3 days and
4 weeks after SCI. BBB scores showed that Mdivi-1 reduced hindlimb motor
dysfunction at 3 days and 4 weeks after SCI. *P < 0.01 vs. Sham. #P < 0.01
vs. SCI.
4 weeks after SCI as our evaluation points. Western blot and
immunofluorescence double labeling showed that the expression
of PCNA increased significantly at 3 days after SCI in rats, which
is consistent with previous studies (Tian et al., 2006). Notably,
Mdivi-1 significantly inhibited the expression of PCNA at 3
days after SCI in rats, suggesting that inhibiting mitochondrial
division after SCI can inhibit the cell cycle progression of
astrocytes, and supporting previous studies (Mitra et al., 2009;
Qian et al., 2012). Surprisingly, we also found some PCNA-
immunoreactivity in GFAP-negative cells that might be microglia
or endothelial cells, which further supports previous studies
(Krum and Khaibullina, 2003; Tian et al., 2007).
Following SCI, astrocytes are activated and show hypertrophy
of the cell body, abnormal proliferation, and upregulation of
GFAP (Tang et al., 2003; Bramanti et al., 2010). They rapidly
secrete a variety of inhibitory proteins, especially CSPGs, and
ultimately form the glial scar tissue in the SCI lesion, which
is the physical and biochemical barrier of repair, and is not
conducive to the growth or regeneration of axons (Tang et al.,
2003; Yuan and He, 2013). In addition to an increase in
astrocyte number at the lesion site in response to SCI injury,
GFAP production, a feature of astrogliosis, also increases, and
its production can reflect the changes in number or activation
degree of astrocytes (Jones et al., 2003). Our presentWestern blot
and immunofluorescence studies show that astrocytes undergo
changes in morphology and GFAP expression at 3 days and 4
weeks after SCI, which supports previous studies (Yang et al.,
2009; Bramanti et al., 2010). Importantly, Mdivi-1 significantly
inhibited the expression of GFAP and astrocyte performance after
SCI, suggesting that inhibition of mitochondrial division can
inhibit astroglial proliferation and hypertrophy after SCI.
CSPGs are extracellular matrix molecules that are widely
expressed throughout the developing and adult CNS (Bradbury
et al., 2002). In vitro studies demonstrate their potential to
restrict neurite outgrowth, and it is believed that CSPGs also
inhibit axonal regeneration after CNS injury in vivo (Yuan and
He, 2013). After SCI, members of the CSPG family, including
neurocan, brevican, versican and NG2, are upregulated, and
might have important roles in limiting axonal regeneration
(Jones et al., 2003; Tang et al., 2003). Previous studies have
reported that neurocan, secreted by reactive astrocytes, increases
within 2 days in injured spinal cord, peaks at 2 weeks, and
remains persistently elevated for 4 weeks after SCI (Bradbury
et al., 2002; Jones et al., 2003). Our Western blot and
immunofluorescence results showed that neurocan expression
was significantly increased 4 weeks after SCI, whereas Mdivi-1
inhibited the expression of neurocan significantly. This indicates
that inhibition of mitochondrial fission may inhibit astrocyte
proliferation, then inhibit the expression, and secretion of
neurocan, and finally inhibit the formation of biochemical
barriers after SCI. Moreover, results of the hematoxylin-eosin
stain show that Mdivi-1 significantly reduces cavity formation
after SCI, suggesting that inhibition of mitochondrial fission
can also inhibit the formation of the physical glial barrier after
SCI. These results support previous studies (Byrnes et al., 2007;
Zhu et al., 2007; DiMauro and Schon, 2008; Lin et al., 2014)
and contribute to our understanding of the relationship between
mitochondrial fission and astroglial proliferation after SCI.
Our previous results indicate that Mdivi-1 plays a role in
reducing apoptosis by inhibiting the translocation of dynamin-
related protein 1 (Drp1) and Bax to the mitochondria (Li G. et al.,
2015). At the same time, Liu et al. (2015) reported that Mdivi-1
may be an effective therapeutic agent for spinal cord ischemia–
reperfusion injury via activation of large-conductance Ca2+-
activated K+ channels as well as reduction of oxidative stress,
mitochondrial dysfunction and neuronal apoptosis. To further
confirm the protective effect of Mdivi-1 in vivo, we investigated
the survival of neurons directly by immunoïnˇC´uorescence
staining and Nissl staining. Spinal cord neurons were marked
by NeuN (the neuronal marker). The percentage of neurons via
immunoïnˇC´uorescence staining and the number of surviving
neurons via Nissl staining decreased significantly at 4 weeks
after SCI and increased in the Mdivi-1 group, which supports
our previous study. In the present study, we found that Mdivi-
1 can inhibit astroglial proliferation and increase the number of
surviving neurons, but the relationship between these two results
needs further study. In addition, the upregulation of GAP-43 is
considered a useful marker of neurite growth or sprouting after
SCI (Benowitz and Routtenberg, 1997; Irwin and Madsen, 1997).
Notably, in this study, we found that SCI alone led to a limited
upregulation of GAP-43 expression. Moreover, the Mdivi-1-
treated group had a significantly higher expression of GAP-43
at 4 weeks after SCI, which may be related to the promotion of
neuronal survival. However, we cannot rule out the possibility
that the increase in GAP-43 byMdivi-1 is related to the inhibition
of astroglial scar formation (Lin et al., 2014). We also found that
Mdivi-1 significantly mitigated functional deficits as assessed by
the measures of the BBB scale. Our data indicated that Mdivi-1
administration has a protective effect after SCI, which supports
previous studies (Li G. et al., 2015; Liu et al., 2015).
In cancer growth, mitochondria grow continuously
throughout the cell cycle, and the organization of the
mitochondrial network is sophisticatedly controlled across
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the different phases of the cell cycle (Qian et al., 2013).
At the G1/S border, mitochondria form a single, giant
tubular network, which is associated with increased energy
production in order to prepare for the initiation of the
highly energy consuming process—DNA synthesis (Mitra
et al., 2009). In addition, such mitochondrial hyperfusion
also facilitates the mixing of mitochondrial contents such
as mtDNA between adjacent mitochondria, to maintain a
homogenous mitochondrial network within the cell, thus
ensuring proper inheritance following cellular division. The
formation of a highly connected mitochondrial network at
G1/S border is transient. During the subsequent S, G2 and
M phases, the hyperfused mitochondrial network is then
disassembled and becomes increasingly fragmented (Qian
et al., 2013). Notably, mitochondrial fission disorders can
lead to sustained mitochondrial hyperfusion beyond the G1/S
border, which further inhibits mitosis and ultimately cell
proliferation (Qian et al., 2012). Our results indicate that Mdivi-1
inhibits astrocyte activation after SCI. However, whether the
effects of Mdivi-1 on the astroglial phenotype result from
the inhibition of mitochondrial fission in astrocytes directly,
or indirectly via Mdivi’s protective effect against neuronal
apoptosis, warrants further investigation. We will examine
the detailed mechanism of Drp1-mediated mitochondrial
fission during astroglial division using gene knockout and
transfection technology, and confirm whether Mdivi-1 can
inhibit mitochondrial fission in astroglia in the astrocyte
scratch-wound model.
In summary, this is the first study to demonstrate that Mdivi-1
inhibits astrocyte activation and astroglial scar formation, and
contributes to the axonal regeneration after SCI in rats. This
indicates that regulation of mitochondrial dynamics maybe an
effective therapeutic target for SCI. However, as the effect of
Mdivi-1 is not cell specific, we cannot rule out the possibility that
neuroprotection by Mdivi-1 is associated with the inhibition of
other proliferating cells, such as microglia and endothelial cells,
in the spinal cord after SCI. Further research is needed to clarify
these issues.
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